After receiving FDA approval in February 2022, Amneal Pharmaeuticals and Kashiv Biosciences launched Releuko (filgrastim-ayow) on the US market, making it the fourth biosimilar referencing Neupogen to be commercially available to Americans.
About 10 months after the FDA approved the drug, Releuko (filgrastim-ayow), a biosimilar referencing Neupogen (filgrastim), is now on the US market. The drug developed by Kashiv Biosciences and Amneal Pharmaceuticals is the fourth filgrastim product to enter the market.
Filgrastim products are granulyte colony-stimulating factors used to treat and prevent febrile neutropenia in patients with cancer undergoing chemotherapy. Releuko is the second biosimilar developed by Amneal Pharmaceuticals and Kashiv Biosciences to launch.
“This product is another important oncology therapeutic offering for providers and their patients as we look to make essential medicines more accessible for all,” said Harsher Singh, senior vice president of Amneal Pharmaceutical’s biosciences division, in a company statement.
Releuko was approved in March 2022 for intravenous and subcutaneous use, either as single-dose vials or prefilled syringes, both of which come in a 300-mcg/mL dose and 480-mcg/1.6 mL dose. According to research from IQVIA, the US sales for all filgrastim products for the 12 months prior to August 2022 were $390 million, of which biosimilars accounted for $272 million.
Releuko launches after Zarxio (filgrastim-sndz), Granix (tbo-filgrastim), and Nivestym (filgrastim-aafi). Zarxio launched in September 2015 as the first biosimilar in the United States; it was also the first biosimilar in the European Union. Although Granix is by definition a biosimilar, it is not legally classified as a biosimilar because it was developed and approved prior to the establishment of the biosimilar approval pathway outlined in the Biologics Price Competition and Innovation Act. Nivestym launched in October 2018 and had the shortest approval-to-launch time (3 vs 5 [Zarxio] vs 10 [Releuko] vs 15 months [Granix]).
Kashiv Biosciences and Amneal Pharmaceuticals have 2 other biosimilars in their portfolio: a pegfilgrastim biosimilar (Fylnetra), which was approved by the FDA in May 2022, and a bevacizumab biosimilar (Alymsys), which was approved in April 2022. Alymsys launched in October 2022 for the treatment of several kinds of cancer. Fylnetra is expected to launch during the second half of 2022.
Additionally, Kashiv has 7 biosimilars in its pipeline that will be used in immunology and respiratory, digestive care, cardiovascular conditions, type 2 diabetes, and fertility hormone therapy.
Financial Performance
In its third quarter of 2022 earnings report, Amneal said that it achieved a net revenue of $546 million, an increase of 3.2% compared with the same quarter in 2021 ($529 million). The company said that the growth stemmed from the “consistent performance of Generics and Specialty [divisions], and double-digit growth of AvKARE [its generic pharmaceutical manufacturer].”
“Third quarter results reflect continued solid performance across our diversified portfolio. Over the last several years, we have driven our growth strategy through new product innovation, leveraging key capabilities, and strong execution… As we successfully execute on our strategic priorities, we see our momentum building,” said Chirag and Chintu Patel, co-CEO of Amneal, in a statement.
Switching From Avastin to Bevacizumab-bvzr in CRC, NSCLC Can Reduce Medicare Costs
May 10th 2025Monthly savings from fully converting Medicare patients with metastatic colorectal cancer (CRC) and non-squamous metastatic non-small cell lung cancer (NSCLC) from reference bevacizumab to bevacizumab-bvzr could fund 13,887 and 8,959 additional patient-months of treatment, respectively, according to a cost-effectiveness study.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Targeted Reimbursement Encourages Oncology Biosimilar Use
May 7th 2025Incentivizing physicians with modest financial bonuses may seem like a small step, but in Japan’s outpatient oncology setting, it helped push trastuzumab biosimilars toward broader adoption, demonstrating how even limited reimbursement reforms can reshape prescribing behavior under the right conditions.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.